PLoS ONE · 2020 · 17 citations · 62 references
Multi-drug-resistant OrganismsPathologyFrequent MdroMdro ColonizationDrug ResistanceOncologyAntimicrobial StewardshipRespiratory InfectionInfection ControlRadiation OncologyAntimicrobial ResistanceCancer ResearchHealth SciencesNsclc DiagnosisCancer TreatmentClinical MicrobiologyLung CancerTumor MicroenvironmentAntibioticsBronchial NeoplasmMedicine
Objectives Multidrug-resistant organisms (MDRO) are considered an emerging threat worldwide. Data covering the clinical impact of MDRO colonization in patients with solid malignancies, however, is widely missing. We sought to determine the impact of MDRO colonization in patients who have been diagnosed with Non-small cell lung cancer (NSCLC) who are at known high-risk for invasive infections. Materials and methods Patients who were screened for MDRO colonization within a 90-day period after NSCLC diagnosis of all stages were included in this single-center retrospective study. Results Two hundred and ninety-five patients were included of whom 24 patients (8.1%) were screened positive for MDRO colonization (MDRO pos ) at first diagnosis. Enterobacterales were by far the most frequent MDRO detected with a proportion of 79.2% (19/24). MDRO colonization was present across all disease stages and more present in patients with concomitant diabetes mellitus. Median overall survival was significantly inferior in the MDRO pos study group with a median OS of 7.8 months (95% CI, 0.0–19.9 months) compared to a median OS of 23.9 months (95% CI, 17.6–30.1 months) in the MDRO neg group in univariate (p = 0.036) and multivariate analysis (P = 0.02). Exploratory analyses suggest a higher rate of non-cancer-related-mortality in MDRO pos patients compared to MDRO neg patients (p = 0.002) with an increased rate of fatal infections in MDRO pos patients (p = 0.0002). Conclusions MDRO colonization is an independent risk factor for inferior OS in patients diagnosed with NSCLC due to a higher rate of fatal infections. Empirical antibiotic treatment approaches should cover formerly detected MDR commensals in cases of (suspected) invasive infections.
62
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.2K citations
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.7K citations · Full text
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.2K citations · Full text